- Global Pharma News & Resources

Global Psoriasis Drugs Market Analysis Report 2016-2022 by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors) & Treatment (Topicals, Systemic, Biologics) -

The "Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022" report has been added to's offering.

The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, experiencing a CAGR of 9.4% during the forecast period.

Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Psoriasis Drugs Market Overview

Chapter 5 Global Psoriasis Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

Companies Mentioned

  • AbbVie Inc.
  • Amgen, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation
  • UCB
  • Merck

For more information about this report visit

View source version on

Editor Details

Last Updated: 26-Oct-2018